Orphan Drugs Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
Growth Factors of Orphan Drugs Market
The orphan drugs market size was valued at USD 170.49 billion in 2023, and the market is now projected to grow from USD 189.17 billion in 2024 to USD 468.58 billion by 2032, exhibiting a CAGR of 12.0% during the forecast period of 2024-2032.
The COVID-19 pandemic had a tremendous impact on marketplace boom, leading to increased regulatory approvals. In 2021, marketplace growth continued as studies and development sports by using key players resumed. This fashion is expected to persist, supported via the launch of pipeline applicants for numerous warning signs, indicating regular increase potentialities for the market all through the forecast length.
One important driving aspect in the international marketplace is the growing R&D investments by means of distinguished gamers to develop novel merchandise. With heightened consciousness and expertise of uncommon sicknesses, key biopharmaceutical agencies are advancing strong pipeline candidates for orphan tablets throughout numerous medical trial stages. This recognition on uncommon sickness therapeutics is pushed through the ability for fundamental pharmaceutical breakthroughs and the improvement of blockbuster pills, contrasting with conventional pharmaceutical portfolios.
One of the distinguished traits within the worldwide marketplace is the robust launch of merchandise for ailment symptoms, particularly for uncommon diseases wherein patients are seeking green treatments. Increasing R&D projects and advocacy from affected person groups are driving the creation of newer and more powerful product offerings. These trends have resulted inside the development and advertising and marketing of several blockbuster drugs for cancers, immunological illnesses, and other uncommon disorders, shaping the marketplace appreciably.
Comprehensive Analysis of Orphan Drugs Market
The orphan drugs market growth is rising at an exponential rate due to its market segmentation. This marketplace enlargement successfully affords an in-depth local exam thinking about the dominant deliver and demand forces that effect the enterprise. These segmentations are methodically segregated by therapy area analysis, by drug type analysis, by distribution channel analysis. By therapy area analysis include, oncology, hematology, neurology, endocrinology, cardiovascular, respiratory, immunotherapy, infectious diseases, and others.By drug type analysis include, biologics and non-biologics. By distribution channel analysis include hospital pharmacy, retail pharmacy, online pharmacy, and others.
The North America region lead the orphan drugs market share by benefitting a market size of USD 91.97 billion in 2023 due to good sized expenditure on orphan tablets, robust affected person population, and presence of key market players are using the improvement of sophisticated and innovative products.
The pinnacle players inside the market play a critical function in the enterprise assuring market growth and placing marketplace requirements. These players include, Amgen Inc., Bayer AG, F. Hoffmann-La Roche Ltd, Alexion Pharmaceuticals Inc., Novo Nordisk A/S, Novartis AG, Bristol-Myers Squibb Company, AstraZeneca, DAIICHI SANKYO COMPANY, LIMITED, and GlaxoSmithKline plc are key players in the pharmaceutical market. These market players provide a level-playing competitive landscape.
In February 2024, Rapid Commercialization Partners (RCP) partnered with Orphan Now to assist agencies growing orphan drugs accelerate time to market and get treatments to sufferers round the world greater correctly.
Segmentation Table
Study Period 2019-2032
Base Year 2023
Estimated Year 2024
Forecast Period 2024-2032
Historical Period 2019-2022
Growth Rate CAGR of 12.0% from 2024 to 2032
Unit Value (USD billion)
Segmentation By Therapy Type
Oncology
Hematology
Neurology
Endocrinology
Cardiovascular
Respiratory
Immunotherapy
Infectious Diseases
Others
By Drug Type
Biologics
Non-biologics
By Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Others
By Region
North America (By Therapy Type, By Drug Type, By Distribution Channel, By Country)
U.S.
Canada
Europe (By Therapy Type, By Drug Type, By Distribution Channel, By Country/Sub-Region)
U.K.
Germany
France
Italy
Spain
Scandinavia
Rest of Europe
Asia Pacific (By Therapy Type, By Drug Type, By Distribution Channel, By Country/Sub-Region)
Japan
China
India
Australia
Southeast Asia
Rest of Asia Pacific
Rest of the World (By Therapy Type, By Drug Type, By Distribution Channel)
Please Note: It will take 5-6 business days to complete the report upon order confirmation.
- 1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
- 2. Executive Summary
- 3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 3.4. Market Trends
- 4. Key Insights
- 4.1. Prevalence of Rare Diseases, By Key Countries/Regions, 2023
- 4.2. Pipeline Analysis, By Key Players
- 4.3. New Product Launches
- 4.4. Key Industry Developments: Mergers, Acquisitions & Partnerships
- 4.5. Technological Developments
- 4.6. Impact of COVID-19 on the Global Orphan Drugs Market
- 5. Global Orphan Drugs Market Analysis, Insights and Forecast, 2019-2032
- 5.1. Market Analysis, Insights and Forecast – By Therapy Area
- 5.1.1. Oncology
- 5.1.2. Hematology
- 5.1.3. Neurology
- 5.1.4. Endocrinology
- 5.1.5. Cardiovascular
- 5.1.6. Respiratory
- 5.1.7. Immunotherapy
- 5.1.8. Infectious Diseases
- 5.1.9. Others
- 5.2. Market Analysis, Insights and Forecast – By Drug Type
- 5.2.1. Biologics
- 5.2.2. Non-Biologics
- 5.3. Market Analysis, Insights and Forecast – By Distribution Channel
- 5.3.1. Hospital Pharmacies
- 5.3.2. Retail Pharmacies
- 5.3.3. Online Pharmacies
- 5.3.4. Others
- 5.4. Market Analysis, Insights and Forecast – By Region
- 5.4.1. North America
- 5.4.2. Europe
- 5.4.3. Asia Pacific
- 5.4.4. Rest of the World
- 6. North America Orphan Drugs Market Analysis, Insights and Forecast, 2019-2032
- 6.1. Market Analysis, Insights and Forecast – By Therapy Area
- 6.1.1. Oncology
- 6.1.2. Hematology
- 6.1.3. Neurology
- 6.1.4. Endocrinology
- 6.1.5. Cardiovascular
- 6.1.6. Respiratory
- 6.1.7. Immunotherapy
- 6.1.8. Infectious Diseases
- 6.1.9. Others
- 6.2. Market Analysis, Insights and Forecast – By Drug Type
- 6.2.1. Biologics
- 6.2.2. Non-Biologics
- 6.3. Market Analysis, Insights and Forecast – By Distribution Channel
- 6.3.1. Hospital Pharmacies
- 6.3.2. Retail Pharmacies
- 6.3.3. Online Pharmacies
- 6.3.4. Others
- 6.4. Market Analysis, Insights and Forecast – By Country
- 6.4.1. U.S.
- 6.4.2. Canada
- 7. Europe Orphan Drugs Market Analysis, Insights and Forecast, 2019-2032
- 7.1. Market Analysis, Insights and Forecast – By Therapy Area
- 7.1.1. Oncology
- 7.1.2. Hematology
- 7.1.3. Neurology
- 7.1.4. Endocrinology
- 7.1.5. Cardiovascular
- 7.1.6. Respiratory
- 7.1.7. Immunotherapy
- 7.1.8. Infectious Diseases
- 7.1.9. Others
- 7.2. Market Analysis, Insights and Forecast – By Drug Type
- 7.2.1. Biologics
- 7.2.2. Non-Biologics
- 7.3. Market Analysis, Insights and Forecast – By Distribution Channel
- 7.3.1. Hospital Pharmacies
- 7.3.2. Retail Pharmacies
- 7.3.3. Online Pharmacies
- 7.3.4. Others
- 7.4. Market Analysis, Insights and Forecast – By Country/ Sub-Region
- 7.4.1. U.K.
- 7.4.2. Germany
- 7.4.3. France
- 7.4.4. Italy
- 7.4.5. Spain
- 7.4.6. Scandinavia
- 7.4.7. Rest of Europe
- 8. Asia Pacific Orphan Drugs Market Analysis, Insights and Forecast, 2019-2032
- 8.1. Market Analysis, Insights and Forecast – By Therapy Area
- 8.1.1. Oncology
- 8.1.2. Hematology
- 8.1.3. Neurology
- 8.1.4. Endocrinology
- 8.1.5. Cardiovascular
- 8.1.6. Respiratory
- 8.1.7. Immunotherapy
- 8.1.8. Infectious Diseases
- 8.1.9. Others
- 8.2. Market Analysis, Insights and Forecast – By Drug Type
- 8.2.1. Biologics
- 8.2.2. Non-Biologics
- 8.3. Market Analysis, Insights and Forecast – By Distribution Channel
- 8.3.1. Hospital Pharmacies
- 8.3.2. Retail Pharmacies
- 8.3.3. Online Pharmacies
- 8.3.4. Others
- 8.4. Market Analysis, Insights and Forecast – By Country/ Sub-Region
- 8.4.1. Japan
- 8.4.2. China
- 8.4.3. India
- 8.4.4. Australia
- 8.4.5. Southeast Asia
- 8.4.6. Rest of Asia Pacific
- 9. Rest of the World Orphan Drugs Market Analysis, Insights and Forecast, 2019-2032
- 9.1. Market Analysis, Insights and Forecast – By Therapy Area
- 9.1.1. Oncology
- 9.1.2. Hematology
- 9.1.3. Neurology
- 9.1.4. Endocrinology
- 9.1.5. Cardiovascular
- 9.1.6. Respiratory
- 9.1.7. Immunotherapy
- 9.1.8. Infectious Diseases
- 9.1.9. Others
- 9.2. Market Analysis, Insights and Forecast – By Drug Type
- 9.2.1. Biologics
- 9.2.2. Non-Biologics
- 9.3. Market Analysis, Insights and Forecast – By Distribution Channel
- 9.3.1. Hospital Pharmacies
- 9.3.2. Retail Pharmacies
- 9.3.3. Online Pharmacies
- 9.3.4. Others
- 10. Competitive Analysis
- 10.1. Global Market Share Analysis (2023)
- 10.2. Company Profiles
- 10.2.1. Amgen Inc. (U.S.)
- 10.2.1.1. Overview
- 10.2.1.2. Products & Services
- 10.2.1.3. SWOT Analysis
- 10.2.1.4. Recent Developments
- 10.2.1.5. Strategies
- 10.2.1.6. Financials (Based on Availability)
- 10.2.2. Bayer AG (Germany)
- 10.2.2.1. Overview
- 10.2.2.2. Products & Services
- 10.2.2.3. SWOT Analysis
- 10.2.2.4. Recent Developments
- 10.2.2.5. Strategies
- 10.2.2.6. Financials (Based on Availability)
- 10.2.3. F. Hoffmann-La Roche Ltd (Switzerland)
- 10.2.3.1. Overview
- 10.2.3.2. Products & Services
- 10.2.3.3. SWOT Analysis
- 10.2.3.4. Recent Developments
- 10.2.3.5. Strategies
- 10.2.3.6. Financials (Based on Availability)
- 10.2.4. Alexion Pharmaceuticals Inc. (U.S.)
- 10.2.4.1. Overview
- 10.2.4.2. Products & Services
- 10.2.4.3. SWOT Analysis
- 10.2.4.4. Recent Developments
- 10.2.4.5. Strategies
- 10.2.4.6. Financials (Based on Availability)
- 10.2.5. Novo Nordisk A/S (Denmark)
- 10.2.5.1. Overview
- 10.2.5.2. Products & Services
- 10.2.5.3. SWOT Analysis
- 10.2.5.4. Recent Developments
- 10.2.5.5. Strategies
- 10.2.5.6. Financials (Based on Availability)
- 10.2.6. Novartis AG (Switzerland)
- 10.2.6.1. Overview
- 10.2.6.2. Products & Services
- 10.2.6.3. SWOT Analysis
- 10.2.6.4. Recent Developments
- 10.2.6.5. Strategies
- 10.2.6.6. Financials (Based on Availability)
- 10.2.7. Bristol-Myers Squibb Company (U.S.)
- 10.2.7.1. Overview
- 10.2.7.2. Products & Services
- 10.2.7.3. SWOT Analysis
- 10.2.7.4. Recent Developments
- 10.2.7.5. Strategies
- 10.2.7.6. Financials (Based on Availability)
- 10.2.8. AstraZeneca (U.K.)
- 10.2.8.1. Overview
- 10.2.8.2. Products & Services
- 10.2.8.3. SWOT Analysis
- 10.2.8.4. Recent Developments
- 10.2.8.5. Strategies
- 10.2.8.6. Financials (Based on Availability)
- 10.2.9. DAIICHI SANKYO COMPANY, LIMITED (Japan)
- 10.2.9.1. Overview
- 10.2.9.2. Products & Services
- 10.2.9.3. SWOT Analysis
- 10.2.9.4. Recent Developments
- 10.2.9.5. Strategies
- 10.2.9.6. Financials (Based on Availability)
- 10.2.10. GlaxoSmithKline plc (U.K.)
- 10.2.10.1. Overview
- 10.2.10.2. Products & Services
- 10.2.10.3. SWOT Analysis
- 10.2.10.4. Recent Developments
- 10.2.10.5. Strategies
- 10.2.10.6. Financials (Based on Availability)
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook